New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
05:55 EDTTEVA, TEVA, TEVA, TEVA, JNJ, JNJ, JNJ, JNJ, NSI, NSI, NSI, NSI, CUR, CUR, CUR, CUR, ALKS, ALKS, ALKS, ALKS, ITCI, ITCI, ITCI, ITCI, TRGT, TRGT, TRGT, TRGT, ADHD, ADHD, ADHD, ADHD, AZN, AZN, AZN, AZN, LLY, LLY, LLY, LLYAmerican Society of Clinical Psychopharmacology to hold annual meeting
54th Annual Meeting of ASCP to be held in Hollywood, Florida on June 16-19.
News For TEVA;AZN;ADHD;TRGT;ITCI;ALKS;CUR;NSI;JNJ;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
January 26, 2016
10:06 EDTALKSOptions with decreasing implied volatility
Options with decreasing implied volatility: SRPT GNC ALKS CALM NFLX CREE FFIV COH ISRG IBM
09:29 EDTJNJJohnson & Johnson said it 'has been and will continue to be active in M&A'
Subscribe for More Information
09:24 EDTJNJJohnson & Johnson expects 'healthy growth' in Pharma for 2016
Cites that it will not be as strong as in 2015. The company said it remains "very committed" to Medical Devices business.
09:16 EDTJNJJohnson & Johnson sees 2016 effective tax rate of 19.5%-20.5%
Subscribe for More Information
09:14 EDTJNJJohnson & Johnson says gains on 2016 divestitures will be lower than 2015 level
Subscribe for More Information
09:12 EDTJNJJohnson & Johnson ended Q4 with $18.5B of net cash
Subscribe for More Information
08:55 EDTJNJJohnson & Johnson expects to continue grow half from M&A, half internally
08:54 EDTJNJJohnson & Johnson expects to grow faster than healthcare market for 5 years
Subscribe for More Information
06:45 EDTJNJJohnson & Johnson sees FY16 adjusted EPS $6.43-$6.58, consensus $6.37
Subscribe for More Information
06:43 EDTJNJJohnson & Johnson reports Q4 adjusted EPS $1.44
Subscribe for More Information
06:42 EDTJNJJohnson & Johnson reports Q4 EPS $1.15, consensus $1.14
Subscribe for More Information
January 25, 2016
14:29 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
12:42 EDTJNJEarnings Watch: J&J shares little changed since last earnings report
Johnson & Johnson (JNJ) is scheduled to report fourth quarter earnings before the market opens on Tuesday, January 26, with a conference call scheduled for 8:30 am ET. Johnson & Johnson is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. EXPECTATIONS: Analysts are looking for earnings per share of $1.42 on revenue of $17.88B, according to First Call. The consensus range for EPS is $1.39-$1.44 on revenue of $17.57B-$18.31B. LAST QUARTER: On October 13, Johnson & Johnson reported third quarter EPS of $1.49 on revenue of $17.1B. The company's Q3 EPS results exceeded average analyst expectations of $1.45 but its revenue came in less than analysts' expectations of $17.54B. With its Q3 results, the drug giant narrowed its EPS view for the year to $6.15-$6.20 from $6.10-$6.20, while maintaining its sales outlook of $75B-$76B. Worldwide Consumer sales of $3.3B for Q3 represented a decrease of 7.7% versus the prior year, consisting of an operational increase of 3.1% and a negative impact from currency of 10.8%. Worldwide Pharmaceutical sales of $7.7B for the third quarter represented a decrease of 7.4% versus the prior year with an operational decrease of 0.3% and a negative impact from currency of 7.1%. Domestic sales decreased 4.5%; international sales decreased 11.1%, which reflected an operational increase of 5.5% and a negative currency impact of 16.6%. Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 10.1%, domestic sales increased 11.5% and international sales increased 8.5%. Worldwide operational sales growth was driven by new products and the strength of core products. New product sales growth was negatively impacted by lower sales of Olysio/Sovriad due to competitive entrants. Strong growth in new products include Invokana/Invokamet, for the treatment of adults with type 2 diabetes; Imbruvica, an oral, once-daily therapy approved for use in treating certain B-cell malignancies, or blood cancers; Xarelto, an oral anticoagulant; and Zytiga, an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer. On January 19, Johnson & Johnson announced restructuring actions in its Medical Devices unit. The actions are expected to result in annualized pre-tax cost savings of $800M to $1B, the majority of which is expected to be realized by the end of 2018, including approximately $200M in 2016. With its restructuring announcement the company reiterated its prior adjusted EPS view of $6.15- $6.20. STREET RESEARCH: On December 18, Atlantic Equities analyst Steve Chesney initiated Johnson & Johnson with a Neutral rating and $95 price target. On December 1, Barclays analyst Geoff Meacham upgraded Johnson & Johnson to Overweight after assuming coverage of the name. J&J should post a strong year in 2017 and will likely boost its orphan diseases or oncology pipeline via capital deployment, Meacham tells investors in a research note. He raised his price target for shares to $115 from $101. PRICE ACTION Since reporting its Q3 results, Johnson & Johnson shares are up approximately 1%, and they are currently trading up fractionally in afternoon trading ahead of Tuesday's earnings report.
12:17 EDTJNJJohnson & Johnson technical notes before earnings
The key level for the shares heading into earnings is at the $90 to $88 area, which has been a zone of support since late 2013. If the news is bearish, shares could retest this area. A breakdown below $90 would confirm a long-term topping process is underway. If the news is bullish, the first important resistance level is at the $100 area. A breakout above $100 would put the 52-week high at $105.49 up as the next major upside objective.
10:00 EDTADHDOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 8x8, Inc. (EGHT) initiated with a Buy at Summit Research... ARI Network (ARIS) initiated with an Outperform at Barrington... Alcobra (ADHD) initiated with an Outperform at Oppenheimer... CNO Financial (CNO) initiated with a Hold at Deutsche Bank... Expedia (EXPE) initiated with an Outperform at Wells Fargo... Gartner (IT) initiated with an Overweight at Atlantic Equities... MAG Silver (MVG) initiated with a Buy at Roth Capital... Mitek Systems (MITK) initiated with an Outperform at Northland... Priceline (PCLN) initiated with a Market Perform at Wells Fargo... QTS Realty Trust (QTS) initiated with a Buy at SunTrust... Seres Therapeutics (MCRB) initiated with a Buy at H.C. Wainwright.
08:36 EDTLLYFDA accepts supplemental NDA for Eli Lilly and Boehringer's Jardiance
Subscribe for More Information
07:21 EDTADHDAlcobra initiated with an Outperform at Oppenheimer
Oppenheimer analyst Akiva Felt started Alcobra with an Outperform rating and $16 price target.
07:01 EDTALKSAlkermes announces initiation of Phase 1 ALKS 7119 study
Alkermes announced the initiation of a phase 1 clinical study of ALKS 7119, an oral, investigational drug candidate being developed for the treatment of agitation in patients with Alzheimer's disease and other central nervous system indications. The double-blind, placebo-controlled study will evaluate the safety and tolerability of single ascending doses of ALKS 7119 in approximately 60 healthy subjects. ALKS 7119 is a novel small molecule that acts on multiple key receptor systems in the brain. The randomized, double-blind, placebo-controlled, multi-cohort, phase 1 study will investigate the safety and tolerability of single ascending doses of ALKS 7119 following oral administration in approximately 60 healthy male adults. The study will also include a battery of psychometric assessments, which are intended to provide preliminary insight into the potential human pharmacodynamic response. Results from this phase 1 study are expected in the second half of 2016.
06:53 EDTAZN, JNJGlaxo, Astra, J&J partner with universities in drug research fund, Reuters says
Subscribe for More Information
January 24, 2016
11:02 EDTALKSStocks post weekly gain after oil rebounds
Stocks recovered late in the week to post their first weekly gain of the new year as equities continue to be correlated closely with the oil market. A plunge in oil led equities lower early in the holiday shortened week, but as oil prices rebounded to close the week out, the major averages followed suit. MACRO NEWS: In the U.S., the consumer price index fell 0.1% during December, versus expectations for a flat reading. The core reading, which excludes food and energy, showed prices rose 0.1% from the prior month, versus expectations for an increase of 0.2%. Initial jobless claims rose to 293,000 last week, topping the expectation for 278,000 first-time claims. Markit's flash manufacturing Purchasing Managers' Index for January rose 1.5 points to 52.7, better than the 51.0 reading that was expected. Existing home sales climbed 14.7% to a 5.46M rate in December, topping the 5.2M rate that was forecast... In Asia, China's national bureau of statistics estimated that GDP growth slowed to 6.8% in the last quarter of the year, dipping from 6.9% growth in the previous quarter. China's industrial output rose 5.9% from a year earlier in December, compared with the consensus forecast for a 6% increase. Japan's Nikkei average was down early in the week, even falling into bear market territory, but rallied nearly 6% on Friday after the Nikkei Asian Review said that the Bank of Japan is taking a "serious look" at additional easing... In Europe, the European Central Bank left its key interest rates unchanged. However, at an associated press conference, ECB President Mario Draghi acknowledged downside risks were increasing again, meaning the bank may need to "review and possibly reconsider" its monetary policy stance at its next meeting in March. Markit's flash PMI for the euro zone slid to an 11-month low of 53.5, missing expectations for a more modest dip to a 54.2 reading. The International Monetary Fund cut its global growth forecasts for the third time in less than a year. The IMF now estimates that the world economy will grow 3.4% this year and 3.6% next year, down from its prior forecasts of 3.6% and 3.8% growth, respectively. COMPANY NEWS: On Tuesday, Morgan Stanley (MS) advanced 1% after its earnings and revenue topped analysts' consensus forecast. Big bank peer Bank of America (BAC) slid 1% after its earnings also beat expectations but its revenue narrowly missed the consensus estimate... On Wednesday, IBM (IBM) slid nearly 5% after reporting better than expected earnings and revenue for the fourth quarter, but forecasting below-consensus profits for the new year... On Thursday, Verizon (VZ) was among the best performers on the Dow, advancing over 3% after its earnings, revenue and wireless subscriber additions all topped expectations. Conversely, fellow Dow member Travelers (TRV) slid almost 1% after releasing its own quarterly results... On Friday, American Express (AXP) sunk more than 12% after the card issuer reported stronger than expected quarterly results but its 2017 profit guidance came in below the consensus outlook. The company's pledge to take out $1B in costs by the end of 2017 did little to change the mood of analysts or investors. Fellow Dow member GE (GE) slid a bit more than 1% after reporting better than expected earnings but lower than expected quarterly revenue... Schlumberger (SLB) shares gained 6% after the oil services giant reported earnings that topped expectations, approved a quarterly dividend of 50c per share and a new share repurchase program of $10B and said it plans to cut 10,000 more jobs... Netflix (NFLX) reported fourth quarter earnings that beat analyst estimates, powered by better than expected international subscriber growth. The numbers were met with positive commentary by several research firms, though decelerating U.S. subscriber growth was highlighted by bears as a warning sign for the company... Deutsche Bank (DB) disclosed that it expects a EUR2.1B net loss for the quarter due to a number of charges, including expected litigation costs of EUR1.2B... Xilinx (XLNX) advanced after reporting its third quarter numbers. The news may have been overshadowed, however, by a regulatory filing showing new agreements with its top executives, with several analysts highlighting that the change could signal a takeover is in the cards in the future... Alkermes (ALKS) plunged more than 44% after disclosing that two of three Phase 3 studies of its experimental depression disorder treatment did not meet their primary efficacy endpoints. INDEXES: For the four-day week, the Dow gained about 0.67% to close at 16,093.51, the S&P 500 rose about 1.4% to close at 1,906.90, and the Nasdaq increased about 2.3% to close at 4,591.18.
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use